Microbicides 2004

Microbicides 2004

Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411

02002 A SAFETY STUDY OF DEXTRIN SULPHATE VAGINAL MICROBICIDE

02092_3 VAGINAL HYGEINE PRACTICES IN A LONDON, UK POPULATION

02104 A PHASE-TWO SAFETY STUDY OF PRO 2000/5 GEL IN SEXUALLY ACTIVE FEMALES IN UGANDA

02249 PHASE 1 MULTI-DOSE SAFETY AND ACCEPTABILITY STUDY OF 6% CELLULOSE SULFATE (CS)

02417 VAGINAL FLUID SLPI IS RELATED TO VAGINAL FLORA AND HORMONAL CONTRACEPTION

02420_1 INTRA-VAGINAL DISTRIBUTION OF CELLULOSE SULFATE

02436 SAFETY, ACCEPTIBILITY AND EFFICACY OF A PENILE MICROBICIDE WIPE

02440 VAGINAL HYGIENE AND USE OF INTRAVAGINAL PRODUCTS AMONG WOMEN IN RURAL SW UGANDA

02449 PHASE 1 MULTI-DOSE SAFETY AND ACCEPTABILITY STUDY OF 6% CELLULOSE SULFATE (CS)

02454 THE EFFECT OF THE UNPROTECTED INTERCOURSE ON THE VAGINAL ENVIRONMENT: COLPOSCOPY AND OTHER MARKERS

02463 SAFETY OF CARRAGUARD® AMONG HIV-POSITIVE WOMEN AND MEN IN SOUTH AFRICA

02534 QUANTITATIVE AND QUALITATIVE DETERMINATION OF THE VAGINAL MICROBIAL FLORA BY REAL TIME PCR

02603 EFFECT OF 0.5% PRO 2000/5 GEL ON INFECTIOUS HIV-1 AND INFLAMMATORY MEDIATORS IN CERVICOVAGINAL SECRETIONS

02655 VAGINAL TENOFOVIR GEL TOLERABILITY IN HIV-UNINFECTED WOMEN AND ABSTINENT HIV-INFECTED WOMEN:HPTN 050

02674 REACHING CONSENSUS: DEVELOPING AN AGREED CLINICAL TRIAL PROTOCOL FOR A MULTI-CENTRE MICROBICIDE RCT

02676_1 SAFETY OF CARRAGUARD USE BY HETEROSEXUAL MEN IN A SIX MONTH CLINICAL TRIAL IN THAILAND

02685 IMAGING THE DISTRIBUTION OF A RECTAL MICROBICIDE GEL AND SEMEN SURROGATE IN THE LOWER GI TRACT